Full Press Release Details
NeOnc Technologies (Nasdaq: NTHI) Announces
AI-Driven Findings Showing Ultrasound Enhances the Potency
of an Already Effective NEO100 in Treating Primary
and Metastatic Brain Tumors
CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE)
- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics
for central nervous system (CNS) cancers, today announced newly published preclinical findings from a research collaboration at the University
of Southern California (USC). The study, now available on bioRxiv (https://www.biorxiv.org/content/10.1101/2025.11.25.690556v1), demonstrates
that ultrasound further enhances and amplifies NEO100's therapeutic potency, driving strong antitumor effects across multiple primary
and metastatic brain tumor types.
Utilizing an AI-driven, 3D-bioprinted New Approach
Methodology (NAM), researchers at USC, led by Dr. Josh Neman-Associate Professor of Neurological Surgery and Chief Clinical Officer
of NTHI-identified NEO100 as a leading sonodynamic therapy agent. This NAM platform-built on NTHI-patented rapid magnetic
3D bioprinting technology (US Patent 11,788,057)-facilitates the rapid generation of physiologically relevant patient-derived tumor
organoids within hours, rather than the weeks typically required by conventional methods, thereby significantly accelerating biomedical
research and aligning with NIH objectives to minimize animal testing.
An AI-driven positive-unlabeled neural network,
trained on over 200 molecular descriptors, was employed to predict compounds most likely to respond to focused ultrasound, penetrate the
blood-brain barrier, and exhibit potent sonodynamic therapeutic activity. Throughout this extensive AI screening initiative, the
platform consistently identified NEO100 as a leading predicted sonosensitizer. Validation studies on rapidly bioprinted tumor spheroids-including
glioblastoma, pediatric medulloblastoma, high-grade meningioma, and breast- and lung-to-brain metastases-demonstrated that NEO100
displayed markedly enhanced tumor-killing activity when combined with focused ultrasound parameters. Together, these results support moving
NEO100 combined with focused ultrasound into future clinical trials for a wide range of primary and metastatic brain tumors.
"This breakthrough provides strong external
validation for NEO100's potential as a first-in-class, noninvasive sonodynamic therapeutic. The integration of AI, 3D bioprinting,
and ultrasound significantly expands NEO100's commercial and clinical opportunity beyond current indications," said Amir Heshmatpour,
Executive Chairman and President of NTHI.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage
life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address
the persistent challenges in overcoming the blood-brain barrier. The company's NEO drug development platform has produced
a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents
have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas.
NeOnc's NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track
and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University
of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc
patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology,
Important Cautions Regarding Forward Looking
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will,"
"should," "intend," "expect," "plan," "budget," "forecast," "anticipate,"
"believe," "estimate," "predict," "potential," "continue," "evaluating,"
or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of
future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include,
among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations
based on information available at this time, but future events may differ materially from those anticipated.
The "Risk Factors" section of our
most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that
report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially
from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications
to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any
forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable
securities laws and regulations.
"NEO100" and NEO "212"
are registered trademarks of NeOnc Technologies Holdings, Inc.